welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- Anorectal Functional Outcome After Repeated Transanal Endoscopic MicrosurgeryAIM : To evaluate the status of anorecta...
- Revealing the Power of the Rare Disease Community With State-of-the Art Collaborative, Trustworthy, Digital Educatio...The growth of online communities in ...
- Prospective Randomized Study of Sulindac versus Calcium and Calciferol for Upper Gastrointestinal Polyps in Familial...Eighteen patients with familial adenomat...
- Bonnies Diary Nov 07https://jtvcancersupport.com/embed/26653...
- Proctocolectomy for Ulcerative Colitis or Familial Adenomatous Polyposishttps://www.youtube.com/watch?v=zlxBwxKX...
- The J-Pouch Group Dietary GuidelinesGood nutrition plays an essential role i...
- The Evolution of Prophylactic Colorectal Surgery for Familial Adenomatous PolyposisINTRODUCTION : Over the past 50 years, p...
English
Portuguese